[Treatment of urinary tract infections with SolcoUrovac]

Urinary tract infections are among the most common infections found in women. If recurrences or reinfections become frequent treatment can be problematic. Immunisation of the patients by vaccinating them against urinary tract pathogens offers a possibility of managing these infections. In clinical trials we tested SolcoUrovac, a new vaccine to counteract bacterial pathogens, with regard to efficacy, frequency of recurrence, and tolerance. 113 of the 118 patients included in this study with bacteriuria (urine culture germ count greater than or equal to 10(5)/ml), had acute cystitis. 47 of these patients had recurring urinary tract infections. Follow-up examinations were conducted after 2, 3, 4, 5, 6 and 12 months. A urine culture assay was performed during each examination, as well as a relevant bacterial differentiation test and a urine sediment evaluation. Two to six weeks after termination of the vaccination series 72.6% of the patients were largely free from signs and symptoms. The rate of recurrence/reinfection dropped from 2.5 to 0.24 infections for a period of 12 months. After one year, 94 of the patients (80%) were still free from reinfection.